IMMUNOVANT INC. DL-,0001

Immunovant shares rose to a 52-week high of $41.37 and are currently trading at $41.44. Market capitalization is around $8.48 billion, and total return over the past year is about 169%. An analysis by InvestingPro rates the stock as overvalued relative to its fair value. » More on de.investing.com

Immunovant’s stock reached a 52-week high of $39.28, bringing market capitalization to $8.01 billion after a one-year gain of 130.79%. Analysts raised price targets—H.C. Wainwright $40, BofA $43 and Stifel $49—citing convincing Phase 2 response rates for IMVT-1402 in rheumatoid arthritis (ACR20/50/70). Roivant reported a Q4 EPS miss but emphasized strategic growth and a strong cash position. The positive trial data are currently driving investor sentiment and future share-price expectations. » More on de.investing.com

H.C. Wainwright lifted its price target for Immunovant to $40 from $35 and kept a Buy rating after Phase 2 rheumatoid arthritis data showed high response rates and efficacy despite prior exposure to advanced therapies. The firm raised the probability of success for IMVT-1402 in RA to 55% and increased its EV/sales multiple to 10x. BofA also raised its target to $43 and boosted peak sales forecasts for IMVT-1402 to $6.8 billion, citing stronger contributions from Graves’ disease and severe RA. IMVT-1402 is a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). » More on finance.yahoo.com

Immunovant will publish the quarterly financials for the period ended March 31, 2026, on May 20, 2026. Sixteen analysts on average expect a loss per share of -0.592 USD (prior year: -0.640 USD). For the quarter and the fiscal year, analysts forecast median revenues of 0.0 million USD and an average annual loss of -2.612 USD per share. » More on finanzen.net

Two phase‑3 studies of Batoclimab in moderate-to-severe thyroid eye disease failed to meet the primary endpoint of a proptosis responder rate ≥2 mm at week 24. Safety data showed no new signals; the initial high-dose phase produced greater improvements than the low-dose phase. Immunovant will review the Batoclimab program with partner HanAll and will focus going forward on developing IMVT‑1402, with topline data in Graves disease expected in 2027. The company has a strong balance sheet, giving room for alternative programs. » More on de.investing.com